Compositions for treating cardiovascular diseases

Patent metadata

Field	Value
Publication number	US-9427422-B2
Application number	US-201414520159-A
Country	US
Kind code	B2
Filing date	Oct 21, 2014
Priority date	Oct 29, 2010
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
a) an anti-hyperlipidemic agent having a log P value of more than 2.6; and
b) at least 80% (v/v) of a pharmaceutically-acceptable lipid-adjuvant, wherein the pharmaceutically-acceptable lipid-adjuvant is a fatty acid having at least 12 carbons, a glycerolipid, a sterol lipid, a prenol lipid, a saccharolipid, or a polyketide,
wherein the pharmaceutical composition is formulated to be a solid at 15° C. or lower and have a melting point temperature of about 30° C. or higher.

2. The pharmaceutical composition according to claim 1 , wherein the anti-hyperlipidemic agent has a log P value of more than 2.8.

3. The pharmaceutical composition according to claim 1 , wherein the anti-hyperlipidemic agent comprises a fibrate or a statin.

4. The pharmaceutical composition according to claim 3 , wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Fenofibrate, or a combination thereof.

5. The pharmaceutical composition according to claim 3 , wherein the statin comprises Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, or a combination thereof.

6. The pharmaceutical composition according to claim 1 , wherein the concentration of the fibrate or the statin is at least 50 mg/mL.

7. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable lipid-adjuvant comprises a saturated fatty acid, an unsaturated fatty acid, or any combination thereof.

8. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable lipid-adjuvant comprises a monoglyceride, an acetylated monoglyceride, a diglyceride, an acetylated diglyceride, a triglyceride, an acetylated triglyceride, or any combination thereof.

9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically-acceptable lipid-adjuvant comprises a triglyceride, an acetylated triglyceride, or any combination thereof.

10. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable lipid-adjuvant is in an amount of about 80% (v/v) to about 97% (v/v).

11. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable lipid-adjuvant is in an amount of about 80% (v/v) to about 93% (v/v).

12. The pharmaceutical composition according to claim 11 , wherein the pharmaceutically-acceptable lipid-adjuvant is in an amount of about 85% (v/v) to about 93% (v/v).

13. The pharmaceutical composition according to claim 12 , wherein the pharmaceutically-acceptable lipid-adjuvant is in an amount of about 88% (v/v) to about 93% (v/v).

14. The pharmaceutical composition according to claim 13 , wherein the pharmaceutically-acceptable lipid-adjuvant is in an amount of about 80% (v/v) to about 97% (v/v).

15. The pharmaceutical composition according to claim 14 , further comprising a pharmaceutically-acceptable stabilizing agent.

16. A pharmaceutical composition comprising:
a) a fibrate and/or a statin; and
b) at least 80% (v/v) of a pharmaceutically-acceptable glycerolipid,
wherein the pharmaceutical composition is formulated to be a solid at a temperature of 15° C. or lower and have a melting point temperature of about 30° C. or higher.

17. The pharmaceutical composition according to claim 16 , wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Fenofibrate, or a combination thereof.

18. The pharmaceutical composition according to claim 16 , wherein the statin comprises Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, or a combination thereof.

19. The pharmaceutical composition according to claim 16 , wherein the pharmaceutically-acceptable lipid-adjuvant comprises a monoglyceride, an acetylated monoglyceride, a diglyceride, an acetylated diglyceride, a triglyceride, an acetylated triglyceride, or any combination thereof.

20. The pharmaceutical composition according to claim 19 , wherein the pharmaceutically-acceptable lipid-adjuvant comprises a triglyceride, an acetylated triglyceride, or any combination thereof.

Assignees

• Infirst Healthcare Ltd

Inventors

• Bannister Robin Mark
• Brew John
• Dilly Suzanne Jane
• Stoloff Gregory Alan
• Caparros-Wanderley Wilson

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title